Authors: Seifirad S PMID: 32575019 PMCID: PMC7297676 DOI: 10.1016/j.mehy.2020.110005 Abstract Cytokine storm, multiorgan failure, and particularly acute respiratory distress syndrome (ARDS) is the leading cause of mortality and morbidity in patients with COVID-19. A fulminant ARDS kills the majority of COVID-19 victims. Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), is a novel anti-fibrotic agent with trivial adverse effects. Pirfenidone is [...]

Authors: Reiter RJ, Sharma R, Ma Q, Liu C, Manucha W, Abreu-Gonzalez P DOI: https://doi.org/10.32794/mr11250068 Abstract COVID-19 has infected hundreds of thousands and killed tens of thousands of people worldwide and it continues to ravage societies as well as fiscal and economic stability of several countries. Currently, several drugs that were designed for other [...]

Coronavirus disease 2019 (COVID-19) is sweeping the globe. Despite multiple case-series, actionable knowledge to tailor decision-making proactively is missing. Can a statistical model accurately predict infection with COVID-19?

Authors: Elharrar X, Trigui Y, Dois AM, Touchon F PMID: 32412581 PMCID: PMC7229532 DOI: 10.1001/jama.2020.8255 Abstract This case series describes the proportion of awake, nonintubated inpatients with COVID-19 and hypoxemic respiratory failure requiring oxygen supplementation whose Pao2 increased ≥20% with prone positioning, and their respiratory status after resuming supine positioning. Keywords: prone positioning, COVID-19, hypoxemic [...]

Authors: Poor HD, Ventetuolo CE, Tolbert T, Chun G, Serrao G PMID: 32508062 PMCID: PMC7288983 DOI: 10.1002/ctm2.44 Abstract Patients with severe COVID-19 disease have been characterized as having the acute respiratory distress syndrome (ARDS). Critically ill COVID-19 patients have relatively well-preserved lung mechanics despite severe gas exchange abnormalities, a feature not consistent with classical ARDS [...]

Authors: Janowitz T, Baglenz E, Pattinson D, Wang TC, Conigliaro J PMID: 32499303 PMCID: PMC7299656 DOI: 10.1136/gutjnl-2020-321852 Abstract Objective: Treatment options for non-hospitalised patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist famotidine is a putative therapy for COVID-19. [...]

Authors: Guan W, Ni Z, Hu Y, Liang W, Ou C, He J PMCID: PMC7266766 doi: 10.1016/j.jemermed.2020.04.004 Abstract The novel coronavirus (SARS-CoV-2, causing COVID-19) was originally isolated in Wuhan, China. This virus spread quickly throughout many countries in Asia and now Europe, Australia, North America, leading the World Health Organization to declare COVID-19 a pandemic. [...]

Authors: Castillo RR, Quizon GR, Juco MJ, Roman AD, de Leon DG, Punzalan FE et al. DOI:https://doi.org/https://doi.org/10.32794/mr11250063. Abstract Treatment for coronavirus disease 2019 (COVID19) pneumonia remains empirical and the search for therapies that can improve outcomes continues. Melatonin has been shown to have anti-inflammatory, antioxidant, and immune-modulating effects that may address key pathophysiologic mechanisms in [...]

Authors: Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R PMID: 32473642 PMCID: PMC7261036 DOI: 10.1186/s12941-020-00368-w Abstract The recent report by Caly et al., describing the antiviral potential of ivermectin against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro arrive to the agenda of potential candidates for COVID-19 treatment. This discovery gave [...]

Authors: Jacobs JJ PMID: 32512289 PMCID: PMC7832094 DOI: 10.1016/j.mehy.2020.109884 Abstract SARS-CoV-2 is a novel beta-coronavirus causing over 200.000 lethal cases within six months of first infecting humans. SARS-CoV-2 causes COVID-19, a form of severe acute respiratory syndrome (SARS). COVID-19 is characterized by two phases: the first resembles the flu with pneumonia, but after about seven [...]